Thromboelastographic Clot Characteristics of Autologous Equine Blood Products After Activation by Autologous Thrombin, Bovine Thrombin, or Calcium Chloride.
- Journal Article
Summary
The article presents a study on thromboelastographic clot capabilities of equine blood products after being activated by autologous thrombin, bovine thrombin, or calcium chloride. The research shows the efficiency of clotting between platelet-rich plasma (PRP) and concentrated platelet-poor plasma (cPPP) among healthy adult horses, with PRP showing the highest clot strength and cPPP exhibiting the least.
Methods
In this study, the clotting variables of PRP and cPPP alongside citrated autologous blood were assessed using the thromboelastographic process amongst healthy horses. These three blood products were activated using either autologous thrombin (a product of the horse’s own body), bovine thrombin, or calcium chloride. This research compares the clotting efficiency of these different activation methods.
- PRP and cPPP were prepared through commercial devices.
- Activation using CaCl2, autologous thrombin, or bovine thrombin.
Results
The study highlighted some interesting results that could inform further research and veterinary interventions.
- PRP presented the highest clot strength and quickest clot rate following activation.
- cPPP showed the weakest clotting strengths, slowest clot rate, and longest clot initiation period, making it the least efficient in the clotting process.
- Bovine thrombin led to the shortest clot initiation time and quickest clot rate, whereas its clot strength was almost at par with CaCl2’s.
- The use of Calcium Chloride (CaCl2) resulted in the longest clot initiation time and the longest time required to reach the maximal clot strength.
- Autologous thrombin, derived from the horses’ own bodies, resulted in the least clot strength.
Conclusions
The paper made important conclusions that can help shape clinical practice moving forward.
- PRP, when combined with either bovine thrombin or CaCl2, provided the most efficient clotting capabilities, hence is recommended for clinical use.
- Even though autologous thrombin has lower efficiency, it can be a potential option for autologous alternative in clinical application due to its low risk of generating adverse immune responses.
- The cPPP, although had insufficient clotting efficiency, may be enough for plasma spray indications.
Cite This Article
Publication
Researcher Affiliations
- Department of Mechanical and Aerospace Engineering.
- Department of Veterinary Medicine, The Ohio State University, Columbus, Ohio.
- Department of Veterinary Medicine, The Ohio State University, Columbus, Ohio.
MeSH Terms
- Animals
- Blood Coagulation
- Calcium Chloride / pharmacology
- Cattle
- Coagulants / pharmacology
- Horses
- Platelet-Rich Plasma / physiology
- Thrombelastography / veterinary
- Thrombin / pharmacology
Citations
This article has been cited 1 times.- Kraeutler MJ, Garabekyan T, Mei-Dan O. The use of platelet-rich plasma to augment conservative and surgical treatment of hip and pelvic disorders. Muscles Ligaments Tendons J 2016 Jul-Sep;6(3):410-419.